CVS Spent Two Decades Building an Empire. Now It’s Taking It Apart

CVS is unwinding two decades of dealmaking just as its results improve. Investors are not sure they like it.

CVS Health (NYSE:CVS) had a good quarter and a bad day. On November 4th it reported adjusted Earnings of $2.09 a share, against the $1.65 analysts expected. It raised its 2026 forecast to at least $8.20 and guided to at least $8.65 for 2027, ahead of the consensus of $8.53. It was the eighth quarter running that it had beaten expectations.

Then came the other news: CVS will split in two. One company keeps the insurer Aetna, the pharmacy-benefit manager Caremark, and the specialty-pharmacy and care-delivery businesses. The other takes roughly 9,000 drugstores, the mail-order pharmacy and a consumer-technology platform. By the close the shares had fallen 12.5% to $79.96, erasing nearly $15bn from a company valued at $117bn.

Why would a firm that says it is acting from strength be punished as if it were fleeing weakness? The answer lies in what is being split, why the board chose this moment, and how an empire built over two decades is meant to be taken apart.

The deal

The line falls between the businesses that insure people and manage their benefits, and the one that serves customers across a pharmacy counter. The group is large: at least $420bn of Revenue expected in 2026, 87m members in its pharmacy-benefit Business and an estimated 37m people insured.

Two of these Assets deserve a closer look. Caremark, the pharmacy-benefit manager, administers prescription coverage for health plans and employers, and stays with the continuing company. Health100, an AI-based platform on which consumers manage their care, goes the other way, to CVS Pharmacy, along with its nearly 30,000 pharmacists, whose services the new company plans to expand.

Shareholders will own shares in both companies. The separation is designed to be tax-free for American federal income-tax purposes and is due in the first half of 2028, subject to final board approval, an effective Form 10 registration statement and confirmation of its tax treatment. Both companies are promised solid investment-grade ratings, strong free Cash Flow and a Dividend that management calls attractive. Goldman Sachs leads the advisers.

An empire assembled

CVS has been through a break-up before. It began in 1963 as a single shop in Lowell, Massachusetts, was sold in 1969 to Melville Corporation, and re-emerged as the core of that group when Melville sold off or spun out the rest in the 1990s.

What followed was buying. Revco in 1997 made CVS the second-biggest drugstore chain by revenue. The Eckerd stores and mail-order business came from J.C. Penney in 2004 for $2.15bn. Two decades ago came Caremark, for $26.5bn, which gave a drugstore chain a large position in pharmacy benefits. Aetna was the boldest bet: agreed in 2017 for $69bn, then the largest healthcare Merger in American history, and ultimately costing about $78bn. The thesis was that an insurer, a pharmacy network and care services under one roof could curb soaring medical costs. Signify Health (about $8bn) and Oak Street Health ($9.5bn) added home and primary care in 2022 and 2023.

Then the model strained. Medical costs rose, and Aetna missed its targets after miscalculating its Medicare Advantage plans. A $5.7bn Goodwill write-down at its care-delivery unit turned the third quarter of 2025 into a loss of $3.13 a share. In 2024 CVS began exploring a break-up and replaced its chief executive, Karen Lynch, with Mr Joyner, who joined Caremark in 1993. Cost cuts, store closures and market exits followed.

Why now

The case from strength

Mr Joyner says this decision was impossible two years ago, when the Medicare business was struggling and the pharmacy division was forecast to shrink by 5%. Since then the numbers have turned. In the third quarter Aetna's adjusted Operating Income rose to $912m from $314m, and the share of premiums spent on care improved to 91.3% from 92.8%. The pharmacy division's adjusted operating income rose 10.6% to $1.64bn, on almost 4% growth in same-store prescriptions and a 23% jump in prescriptions for GLP-1 weight-loss drugs. Operating Cash Flow over nine months was $15.3bn, more than double the $7.2bn of a year earlier. The Leverage target was reached early, and buy-backs resume in the fourth quarter. The company, Mr Joyner insists, is "not doing anything out of a distressed decision".

The structural argument is that the stores have always negotiated with Caremark at arm's length, so the integration worth keeping lies elsewhere: insurance, drug benefits, specialty medicines and care delivery. About 2% of the population drives more than half of pharmacy spending, Mr Joyner notes, which is why he wants the PBM's full toolkit beside an insurer and specialty pharmacy. Management lists four benefits of splitting: focus, tailored Capital allocation, agility and simplicity.

The case from pressure

The stores face a harder business than their profits suggest. Drugstores contend with payment pressure, competition from Amazon and other online pharmacies, and a shift to home delivery that cuts the visits that generate extra purchases. Walgreens sold its Boots business and was bought by a private-equity firm last year. CVS's own pharmacy revenue fell 2.0% in the quarter to $35.5bn even as profit rose, helped by prescription files bought from Rite Aid.

Regulation looms larger. Critics say years of consolidation created conflicts of interest and helped make American healthcare spending the highest in the world. One analyst argues that CVS has more exposure to vertical integration than any rival and chose to move before a court or legislature forced its hand. Another calls the split "a defensive move against regulation rather than an offensive move".

The legal record is real. In September 2024 the Federal Trade Commission filed a complaint against the three largest PBMs, CVS's among them, alleging that they inflated insulin costs. In July 2026 CVS and the FTC announced a proposed settlement that would resolve all outstanding investigations into its PBM and pharmacies, including vertical-integration questions. It awaits a final order. The Justice Department, health officials and state attorneys-general also have inquiries under way, rebate suits are consolidated in New Jersey, and hospitals are suing over the 340B drug-discount programme.

Notably, the insurer and the PBM stay joined; what leaves is the retail arm. CVS has not cited regulation as a motive, saying only that independence will help each company adapt to regulatory change. Both readings can be true: a board can act from strength and still judge the old structure a liability.

How it is meant to work

Contracts in place of ownership. Mr Joyner says the two companies need commercial agreements, not a shared operating structure, and expects the next 15 to 18 months to go on drafting them. Mail service goes with CVS Pharmacy, rebuilt around 90-day supplies that can be delivered, collected in store or picked up at a drive-through. CVS Pharmacy will also seek partnerships with a wider set of payers and PBMs, so its ties to Caremark become matters for negotiation. The quarterly filing shows the scale: $18.1bn of revenue passed between segments in the third quarter, $11.2bn of it recorded by the pharmacy segment, nearly a third of its $35.5bn.

Technology as glue. Health100 is meant to connect the halves. The stores Supply frequent, high-volume contact with consumers; Aetna and Caremark supply the financial data that guides their choices.

The balance sheet. At the end of September the group held $11.7bn of cash and $60.7bn of debt, down from $64.6bn at the end of 2025, rated BBB by Fitch and S&P and Baa3 by Moody's. Both companies are promised solid Investment grade, but how the Debt will be divided has not been said. CVS repurchased no shares in the first nine months of the year, and the $10bn authorised in 2022 is untouched. The dividend stays at $0.665 a quarter.

The bill. Management expects one-time costs, stranded costs and the expense of running two public companies. It calls them manageable and has given no figure.

The market's verdict

Investors had three objections. The first was surprise. The second was the lack of detail: one analyst recalled that CVS promised synergies of at least $500m when it bought Caremark, yet has put no number on unwinding them.

The third was the 2027 arithmetic. Guidance of at least $8.65 beats the consensus, but against the raised 2026 figure it implies growth of about 5.5%. The chief financial officer described it as roughly 13% growth off an adjusted baseline he did not define, and said it assumes buy-backs only offset dilution. The Health Services segment, which houses the PBM, is guided to at least $7bn, a trough, as 340B earnings fall, the selling season weakens and clients lose members. Peers expect earnings to accelerate, and some, more focused on government-sponsored plans, could gain political backing after Democrats won control of Congress in Tuesday's midterms.

Management replies that Caremark won about $6bn of gross new business for 2026, that part of the 2027 membership loss reflects clients' own decisions, that the 2028 pipeline is robust and that 340B earnings should stabilise by the end of 2027. It says it is on course for the upper end of the mid-teens annual EPS growth promised at its investor day, through 2028. The shares edged up about 1% in early pre-market trading the next morning.

What could go wrong

1. The numbers. There are no pro-forma accounts, debt allocation, separate dividends or cost estimate yet. The filing warns that the separation could cost more, take longer, lose its tax-free status or not happen.
2. The contracts. Two decades of in-house dealing must become two companies' agreements.
3. The regulators. The FTC settlement still needs a final order, and the continuing company still pairs an insurer with a PBM.
4. Aetna's recovery. It expects another year of Margin improvement in 2027, but utilisation remains elevated. The share of Medicare Advantage members in plans rated four stars or higher for 2027 fell to more than 69% from more than 81%, and those ratings set Bonus payments in 2028. Aetna still ranks second among large publicly traded Medicare Advantage insurers.
5. The stores alone. Revenue is falling and growth leans on acquired Rite Aid files. Walgreens shows how unforgiving the Economics can be.

Verdict

CVS is betting that the valuable part of its empire is the part that is easy to keep together, and that the part it is releasing was never fully integrated. The logic is coherent and the results behind it are strong. But investors are being asked to trust a structure without its numbers, while the PBM-led segment heads for a trough and the regulatory pressure that critics see behind the move has not gone away. The commercial agreements, the debt split and the cost of separation will say more about the deal than a single day's share price.